

Daniela Romualdi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4902428/publications.pdf>

Version: 2024-02-01

20
papers

2,235
citations

623188

14
h-index

752256

20
g-index

20
all docs

20
docs citations

20
times ranked

2352
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing the Angiography Protocol to Reduce Radiation Dose in Uterine Artery Embolization: The Impact of Digital Subtraction Angiographies on Radiation Exposure. CardioVascular and Interventional Radiology, 2022, 45, 249-254.	0.9	3
2	The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Human Reproduction Open, 2021, 2021, hoab022.	2.3	29
3	What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment. Therapeutic Advances in Reproductive Health, 2020, 14, 263349412090870.	1.3	8
4	Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. Clinical Endocrinology, 2019, 91, 479-489.	1.2	50
5	Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study. Reproductive Sciences, 2018, 25, 269-275.	1.1	56
6	Neuroendocrine Regulation of Food Intake in Polycystic Ovary Syndrome. Reproductive Sciences, 2018, 25, 644-653.	1.1	9
7	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 2018, 110, 364-379.	0.5	759
8	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 2018, 33, 1602-1618.	0.4	1,015
9	Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clinical Endocrinology, 2017, 86, 725-730.	1.2	30
10	Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. Gynecological Endocrinology, 2017, 33, 698-701.	0.7	24
11	Plasmatic and Intracellular Markers of Oxidative Stress in Normal Weight and Obese Patients with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 506-513.	0.6	14
12	Low AMH levels as a marker of reduced ovarian reserve in young women affected by Down's syndrome. Menopause, 2016, 23, 1247-1251.	0.8	2
13	The Role of Anti-Müllerian Hormone in the Characterization of the Different Polycystic Ovary Syndrome Phenotypes. Reproductive Sciences, 2016, 23, 655-661.	1.1	21
14	How Metformin Acts in PCOS Pregnant Women: Insights into insulin secretion and peripheral action at each trimester of gestation. Diabetes Care, 2013, 36, 1477-1482.	4.3	12
15	Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations. Fertility and Sterility, 2011, 96, 374-378.	0.5	32
16	Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertility and Sterility, 2010, 93, 2303-2310.	0.5	49
17	Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. Clinical Endocrinology, 2008, 69, 562-567.	1.2	26
18	Metformin treatment does not affect total leptin levels and free leptin index in obese patients with polycystic ovary syndrome. Fertility and Sterility, 2008, 89, 1273-1276.	0.5	21

#	ARTICLE	IF	CITATIONS
19	Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study. <i>Fertility and Sterility</i> , 2008, 90, 1826-1833.	0.5	45
20	Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2007, 88, 131-138.	0.5	30